<collection><source>PMC</source><date>20201214</date><key>pmc.key</key><document><id>34550</id><infon key="license">NO-CC CODE</infon><passage><infon key="article-id_pmc">34550</infon><infon key="article-id_pmid">11454238</infon><infon key="article-id_publisher-id">1471-2180-1-9</infon><infon key="fpage">9</infon><infon key="journal-title">BMC Microbiology</infon><infon key="lpage">9</infon><infon key="name_0">surname:Cottagnoud;given-names:Philippe</infon><infon key="name_1">surname:Entenza;given-names:Jose M</infon><infon key="name_2">surname:Cottagnoud;given-names:Marianne</infon><infon key="name_3">surname:Que;given-names:Yok-Ai</infon><infon key="name_4">surname:Moreillon;given-names:Philippe</infon><infon key="name_5">surname:T&#228;uber;given-names:Martin G</infon><infon key="section_type">TITLE</infon><infon key="type">front</infon><infon key="volume">1</infon><infon key="year">2001</infon><offset>0</offset><text>Sub-inhibitory concentrations of vancomycin prevent quinolone-resistance in a penicillin-resistant isolate of Streptococcus pneumoniae</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>135</offset><text>What is the background on this?</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>146</offset><text>This study aimed to identify a treatment modality that hinders quinolone resistance in penicillin-resistant pneumococcal infections, as the persistent spread of these strains poses an ongoing danger.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>464</offset><text>What are the outcomes?</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>472</offset><text>The development of trovafloxacin-resistant and high-level ciprofloxacin-resistance was prevented in a penicillin- resistant pneumococcus when it was exposed to increasing concentrations of either trovaslucinate or virofagaric acid selected for the mutants that are resistant to these antibiotics.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>790</offset><text>Remarkable conclusions</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>802</offset><text>This finding may have clinical implications, particularly in relation to the risk associated with a bacterial isolate of quinolone-resistant pneumococci.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>912</offset><text>The most common pathogen in the United States is the gram-negative bacteria, Escherichia coli, which is transmitted through the mouth, noses, and eyes. The pathogen is resistant to vancomycin, a bactericide used in penicillin-resistant Staphylococcus aureus (P. aeruginosa), but resistant to cephalosporins, used in penicillin-resistant E. coli. There is also a sub-group of pathogens that are resistant to vancomycin and cephalosporins, including gram-negative bacilli, and enterococci, which are resistant to vancomycin and cephalosporins.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>923</offset><text>In recent years, the worldwide emergence of penicillin-resistant pneumococci has jeopardized the efficacy of -lactam antibiotics. Furthermore, penilecicles are often resistant to multiple drugs, which means they can limit the choice of alternative compounds. New anti-pneumogenic drugs must combine their abilities to rapidly kill target organisms and inhibit their development, as newer quinolones with good anti&#8211;gram-positive activity such as trovafloxacin may block resistance development.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>2162</offset><text>The combination of vancomycin and trovafloxacin was found to enhance the bactericidal activity of the antibiotic against penicillin-resistant pneumococci in vitro and experimental meningitis in rabbits. However, we have now demonstrated that sub-inhibitory concentrations of 0.03 mg/L vancoramycin also prevented resistance to ciprofloxagarica but not per se (this observation deserves special attention).</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_1</infon><offset>2702</offset><text>Results</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>2710</offset><text>Repeated exposure of WB4 to stepwise increasing concentrations of either trovafloxacin or ciprofloxacin resulted in resistance development against both drugs. Figure 1 indicates that the MIC of trovafloxacin had increased by 32-fold (MIC 4 mg/L) after only five passages. Likewise, the MIC of ciprofloxacin increased 16-fold (8 mg/L) after only three antibiotic passages. In sharp contrast, addition of sub-inhibitory concentrations (&#188; the MIC: 0.03 mg/L) of vancomycin to trovafloxacin completely prevented the emergence of mutants resistant to this drug, and the MIC of trovafloxacin remained unchanged for up to eight cycles (Figure 1). Moreover, addition of vancomycin to ciprofloxacin also reduced resistance development against this compound, albeit not to the same extent as for trovafloxacin. Indeed, a slight increase to 2-fold the MIC (1 mg/L) was observed in this experiment (Figure 2). Addition of &#188; the MIC of vancomycin did not affect the MIC of the test quinolones and resistance to vancomycin has not been observed in quinolone-resistant mutants either (Table 1).</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>3794</offset><text>As previously described, there was a certain amount of cross-resistance between the two test quinolones. Table 1 indicates that resistance to trovafloxacin was accompanied by a parallel increase in the ciprofloxacin MIC (from 0.5 mg/L to &gt; 32 mg/L). On the other hand, selection of resistance with ciprofloxacin only marginally affected the MIC of trovafloxacin (from 0.12 to 0.25 mg/L).</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>4182</offset><text>The difference between these cross-resistance patterns most likely relied in the specific mutations selected by the two drugs. Table 2 presents the mutations in the topoisomerase IV (parC and parE) and gyrase (gyrA and gyrB) genes observed in resistant mutants selected with either of the compounds. Trovafloxacin selected mutations in the parC and the gyrA genes. The parC mutation (Ser79&#8594;Phe) was previously described. Two other parE (Asp435&#8594;Asn, and Ile460&#8594;Val) were recently observed in a clinical isolate of trovafloxacin-resistant pneumococcus, but did not appear in the present experiments. The gyrA mutation (Ser81&#8594;Phe) has been reported as well. This mutation resembles a gyrA (Ser83&#8594;Phe) mutation described in ciprofloxacin-resistant pneumococci, and is likely to be responsible for the cross-resistance pattern between trovafloxacin and ciprofloxacin.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>5055</offset><text>In contrast, resistance to ciprofloxacin was somewhat different. The parC mutation (Ser79&#8594;Tyr) was relatively conserved when compared to the parC mutation selected by trovafloxacin (Ser79&#8594;Phe). Indeed, both substitutions (Tyr and Phe) involve aromatic acids that differ only by one hydroxyl group. On the other hand, the GyrB mutation (Asp435&#8594;Glu) has been described in ciprofloxacin-resistant derivatives, but not in trovafloxacin-resistant clones. Therefore, it is likely that this mutation cannot confer cross-resistance to trovafloxacin.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">title_1</infon><offset>5603</offset><text>Discussion</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>5614</offset><text>Sub-inhibitory concentration of vancomycin prevented the selection of all these mutations, except for the low level resistance mutation to ciprofloxacin (Table 2). Since these vancomycin concentrations did not affect the quinolones' MICs, it was unlikely that mutation prevention was merely due to a combined bacteriostatic effect of the two drugs. An other conceivable explanation for this phenomenon might be an increased intracellular penetration of the quinolones by addition of the cell wall active antibiotic. This would lead to intracellular antibiotic levels above the mutant prevention concentration (MPC) impeding the emergence of mutations. However, this hypothesis is less probable because one would expect a change of the MIC in presence of vancomycin (see Table 1). On the other hand, we did previously show that the combination of vancomycin with quinolones synergically increased the bactericidal effect of these drugs. Therefore, resistance prevention might be due to improved bactericidal killing at the MIC and supra-MIC concentrations, thus lowering the bacterial population below the critical level that allows selection for chromosomal mutations (i.e., below 106-108 CFU). This was indeed the case both in vitro and in rabbits with experimental meningitis.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">title_1</infon><offset>6893</offset><text>Remarkable conclusions</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>6905</offset><text>Similar to the synergistic activity of cell wall active antibiotics and aminoglycosides in enterococci and other gram-positive pathogens, the data presented here is comparable. Although not entirely clear, it plays a significant role in both prevention and treatment effectiveness in severe infections. A similar model could also be used with the combination of cells wall inhibitors plus trovafloxacin or other specific quinolones for pneumoccal infections as well. This observation raises the possibility of combining these two drug interactions associated with vancomycin</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_1</infon><offset>7586</offset><text>Materials and Methods</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>7608</offset><text>Antibiotics and MIC determination</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>7642</offset><text>Trovafloxacin was provided by Pfizer Inc. (Groton, Conn.), ciprofloxacin was purchased from Bayer AG (Wuppertal, Germany), and vancomycin was purchased from Eli Lilly (Geneva, Switzerland). WB4 is a penicillin-resistant isolate (MIC: 4 mg/L) serotype 6 originally isolated from a patient with pneumonia at the University Hospital of Berne, Switzerland, and was grown in C+Y medium. MICs were determined by broth macrodilution methods. The MIC was defined as the lowest concentration that inhibited visible growth after 12 and 24 h of incubation at 37&#176;C.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>8197</offset><text>Selection of quinolone-resistant derivatives in vitro</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>8251</offset><text>Experiments were designed to test the tendency of trovafloxacin and ciprofloxacin to select resistant strains in liquid cultures. Large inocula (107-108 CFU/ml) of WB4 were exposed to stepwise increasing concentrations of antibiotics. Series of tubes containing twofold increasing concentrations of either trovafloxacin or ciprofloxacin were inoculated with WB4 (107-108 CFU/ml), as for the MIC determination. After 12 hours of incubation 0.1 ml samples from the tubes containing the highest antibiotic concentration and still showing turbidity were used to inoculate a new series of tubes containing antibiotic serial dilutions. The experiment was performed during eight cycles. The MIC was determined after each cycle.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>8972</offset><text>In further series, the same experimental protocol was used but vancomycin was added in low concentrations (0.03 mg/L corresponding to &#188; MIC) to the tubes containing serial dilutions of either trovafloxacin or ciprofloxacin. After 12 hours of incubation MIC was determined as described above in tubes containing only either trovafloxacin or ciprofloxacin.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>9329</offset><text>Preparation of chromosomal DNA, PCR amplification and DNA sequence analysis</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>9405</offset><text>Chromosomal pneumococcal DNA was prepared as described. PCR-amplification of the parC, parE, gyrA and gyrB genes were performed according to a published method. PCR-amplification was performed with a GeneAmp PCR System 9700 apparatus (Perkin Elmer). After amplification, PCR products were purified by using a QIAquick PCR purification kit (Quiagen AG, Basel, Switzerland). Nucleotide sequencing of the PCR amplicons was carried out by using the ABI PRISM Dye Terminator Cycle Sequencing Ready Reaction kit according to the protocol of the manufacturer (Perkin Elmer). An ABI PRISM 377 DNA sequencer was used for sequencing. All testing was performed in duplicate.</text></passage><passage><infon key="fpage">213</infon><infon key="lpage">221</infon><infon key="name_0">surname:Bradley;given-names:J</infon><infon key="name_1">surname:Scheld;given-names:WM</infon><infon key="section_type">REF</infon><infon key="source">Clin Infect Dis</infon><infon key="type">ref</infon><infon key="volume">24</infon><infon key="year">1997</infon><offset>10069</offset><text>The challenge of penicillin-resistant Streptococcus pneumoniae meningitis: current antibiotic therapy in the 1990s</text></passage><passage><infon key="fpage">628</infon><infon key="lpage">644</infon><infon key="name_0">surname:Kaplan;given-names:SL</infon><infon key="name_1">surname:Mason;given-names:EO</infon><infon key="pub-id_pmid">9767060</infon><infon key="section_type">REF</infon><infon key="source"> Clin Microbiol Rev</infon><infon key="type">ref</infon><infon key="volume">11</infon><infon key="year">1998</infon><offset>10184</offset><text>Management of infections due to antibiotic-resistant Streptococcus pneumoniae</text></passage><passage><infon key="fpage">233</infon><infon key="lpage">239</infon><infon key="name_0">surname:Chen;given-names:DK</infon><infon key="name_1">surname:McGeer;given-names:A</infon><infon key="name_2">surname:de Azavedo;given-names:JC</infon><infon key="name_3">surname:Low;given-names:DE</infon><infon key="pub-id_pmid">10413735</infon><infon key="section_type">REF</infon><infon key="source">N Engl J Med</infon><infon key="type">ref</infon><infon key="volume">341</infon><infon key="year">1999</infon><offset>10262</offset><text>Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada</text></passage><passage><infon key="fpage">433</infon><infon key="lpage">486</infon><infon key="name_0">surname:Gootz;given-names:TD</infon><infon key="name_1">surname:Brighty;given-names:KE</infon><infon key="pub-id_pmid">8865150</infon><infon key="section_type">REF</infon><infon key="source">Med Res Rev</infon><infon key="type">ref</infon><infon key="volume">16</infon><infon key="year">1996</infon><offset>10345</offset><text>Fluoroquinolone antibacterials: SAR, mechanism of action, resistance, and clinical aspects</text></passage><passage><infon key="fpage">329</infon><infon key="lpage">334</infon><infon key="name_0">surname:Jorgensen;given-names:JH</infon><infon key="name_1">surname:Weigel;given-names:LM</infon><infon key="name_2">surname:Ferraro;given-names:MJ</infon><infon key="name_3">surname:Swenson;given-names:JM</infon><infon key="name_4">surname:Tenover;given-names:FC</infon><infon key="pub-id_pmid">9925527</infon><infon key="section_type">REF</infon><infon key="source">Antimicrob Agents Chemother</infon><infon key="type">ref</infon><infon key="volume">43</infon><infon key="year">1999</infon><offset>10436</offset><text>Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci</text></passage><passage><infon key="fpage">963</infon><infon key="lpage">965</infon><infon key="name_0">surname:Rodoni;given-names:D</infon><infon key="name_1">surname:H&#228;nni;given-names:F</infon><infon key="name_2">surname:Gerber;given-names:CM</infon><infon key="name_3">surname:Cottagnoud;given-names:M</infon><infon key="name_4">surname:Neftel;given-names:K</infon><infon key="name_5">surname:T&#228;uber;given-names:MG</infon><infon key="name_6">surname:Cottagnoud;given-names:P</infon><infon key="pub-id_pmid">10103211</infon><infon key="section_type">REF</infon><infon key="source">Antimicrob Agents Chemother</infon><infon key="type">ref</infon><infon key="volume">43</infon><infon key="year">1999</infon><offset>10588</offset><text>Trovafloxacin in combination with vancomycin against penicillin-resistant pneumococci in the rabbit meningitis model</text></passage><passage><infon key="fpage">508</infon><infon key="lpage">518</infon><infon key="name_0">surname:Lack;given-names:S</infon><infon key="name_1">surname:Hotchkiss;given-names:RD</infon><infon key="pub-id_pmid">14413322</infon><infon key="section_type">REF</infon><infon key="source">Biochim Biophys Acta</infon><infon key="type">ref</infon><infon key="volume">39</infon><infon key="year">1960</infon><offset>10705</offset><text>A study of the genetic material determining an enzyme activity in pneumococcus</text></passage><passage><infon key="name_0">surname:National Committee for Clinical Laboratory Standards</infon><infon key="section_type">REF</infon><infon key="source">Wayne, PA</infon><infon key="type">ref</infon><infon key="year">1993</infon><offset>10784</offset><text>Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically: Approved standard M7-A3. NCCLS,</text></passage><passage><infon key="fpage">1662</infon><infon key="lpage">1667</infon><infon key="name_0">surname:Entenza;given-names:JM</infon><infon key="name_1">surname:Fl&#252;ckiger;given-names:U</infon><infon key="name_2">surname:Glauser;given-names:MP</infon><infon key="name_3">surname:Moreillon;given-names:P</infon><infon key="pub-id_pmid">9257737</infon><infon key="section_type">REF</infon><infon key="source">Antimicrob Agents Chemother</infon><infon key="type">ref</infon><infon key="volume">41</infon><infon key="year">1997</infon><offset>10907</offset><text>Levofloxacin versus ciprofloxacin, flucloxacillin, or vancomycin for treatment of experimental endocarditis due to penicillin-susceptible and -resistant streptococci</text></passage><passage><infon key="name_0">surname:Sambrook;given-names:J</infon><infon key="name_1">surname:Fritsch;given-names:F</infon><infon key="name_2">surname:Manaiatis;given-names:T</infon><infon key="section_type">REF</infon><infon key="source">Cold Spring Harbor, 2nd ed Cold Spring Harbor Laboratory Press,</infon><infon key="type">ref</infon><infon key="year">1989</infon><offset>11073</offset><text>Molecular cloning: a laboratory manual</text></passage><passage><infon key="fpage">2321</infon><infon key="lpage">2326</infon><infon key="name_0">surname:Pan;given-names:WS</infon><infon key="name_1">surname:Ambler;given-names:J</infon><infon key="name_2">surname:Mehtar;given-names:S</infon><infon key="name_3">surname:Fisher;given-names:LM</infon><infon key="pub-id_pmid">8891138</infon><infon key="section_type">REF</infon><infon key="source"> Antimicrob Agents Chemother</infon><infon key="type">ref</infon><infon key="volume">40</infon><infon key="year">1996</infon><offset>11112</offset><text>Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae</text></passage><passage><infon key="fpage">2760</infon><infon key="lpage">2764</infon><infon key="name_0">surname:Janoir;given-names:C</infon><infon key="name_1">surname:Zeiler;given-names:V</infon><infon key="name_2">surname:Kitzis;given-names:M</infon><infon key="name_3">surname:Moreau;given-names:NJ</infon><infon key="name_4">surname:Gutman;given-names:L</infon><infon key="pub-id_pmid">9124836</infon><infon key="section_type">REF</infon><infon key="source">Antimicrob Agents Chemother</infon><infon key="type">ref</infon><infon key="volume">40</infon><infon key="year">1996</infon><offset>11212</offset><text>High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA</text></passage><passage><infon key="fpage">302</infon><infon key="lpage">306</infon><infon key="name_0">surname:Varon;given-names:E</infon><infon key="name_1">surname:Janoir;given-names:C</infon><infon key="name_2">surname:Kitzis;given-names:MD</infon><infon key="name_3">surname:Gutman;given-names:L</infon><infon key="pub-id_pmid">9925523</infon><infon key="section_type">REF</infon><infon key="source"> Antimicrob Agents Chemother</infon><infon key="type">ref</infon><infon key="volume">43</infon><infon key="year">1999</infon><offset>11314</offset><text>ParC and GyrA may be interchangeable initial targets of some fluoroquinolones in Streptococcus pneumoniae</text></passage><passage><infon key="fpage">2000</infon><infon key="lpage">2004</infon><infon key="name_0">surname:Pestova;given-names:E</infon><infon key="name_1">surname:Beyer;given-names:R</infon><infon key="name_2">surname:Ciancotto;given-names:NP</infon><infon key="name_3">surname:Noskin;given-names:GA</infon><infon key="name_4">surname:Peterson;given-names:LR</infon><infon key="pub-id_pmid">10428926</infon><infon key="section_type">REF</infon><infon key="source">Antimicrob Agents Chemother</infon><infon key="type">ref</infon><infon key="volume">43</infon><infon key="year">1999</infon><offset>11420</offset><text>Contribution of topoisomerase IV and DNA gyrase mutations in Streptococcus pneumoniae to novel quinolones</text></passage><passage><infon key="fpage">1177</infon><infon key="lpage">1182</infon><infon key="name_0">surname:Davies;given-names:TA</infon><infon key="name_1">surname:Pankuck;given-names:GA</infon><infon key="name_2">surname:Dewasse;given-names:BE</infon><infon key="name_3">surname:Jacobs;given-names:MR</infon><infon key="name_4">surname:Appelbaum;given-names:PC</infon><infon key="section_type">REF</infon><infon key="source">Streptococcus pneumoniae Antimicrob Agents Chemother</infon><infon key="type">ref</infon><infon key="volume">43</infon><infon key="year">1999</infon><offset>11526</offset><text>In-vitro development of resistance to five quinolones and amoxicillin-clavulanate in</text></passage><passage><infon key="fpage">433</infon><infon key="lpage">438</infon><infon key="name_0">surname:Blondeau;given-names:JM</infon><infon key="name_1">surname:Zhao;given-names:X</infon><infon key="name_2">surname:Hansen;given-names:G</infon><infon key="name_3">surname:Drlica;given-names:K</infon><infon key="section_type">REF</infon><infon key="source"> Antimicrob Agents Chemother</infon><infon key="type">ref</infon><infon key="volume">41</infon><infon key="year">2001</infon><offset>11611</offset><text>Mutant prevention concentration of fluoroquinolones for clinical isolates of Streptococcus pneumoniae</text></passage><passage><infon key="section_type">FIG</infon><infon key="type">title_1</infon><offset>11713</offset><text>Figures and Tables</text></passage><passage><infon key="file">1471-2180-1-9-1.jpg</infon><infon key="id">F1</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>11732</offset><text>shows selection of trovafloxacin resistant mutants of Streptococcus pneumoniae WB4 exposed to stepwise increasing concentrations of trovafloxacin alone or in combination with sub-MIC concentration (&#188; MIC) of vancomycin.</text></passage><passage><infon key="file">1471-2180-1-9-2.jpg</infon><infon key="id">F2</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>11954</offset><text>shows selection of ciprofloxacin resistant mutants of Streptococcus pneumoniae WB4 exposed to stepwise increasing concentrations of ciprofloxacin alone or in combination with sub-MIC concentration (&#188; MIC) of vancomycin.</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>12176</offset><text>MICs of trovafloxacin and ciprofloxacin alone and in combination with subinhibitory concentrations of vancomycin</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version="1.0" encoding="UTF-8"?&gt;
&lt;table frame="hsides" rules="groups"&gt;&lt;thead&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align="center" colspan="5"&gt;&lt;bold&gt;MIC(mg/L)&lt;/bold&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td colspan="5"&gt;&lt;hr/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td/&gt;&lt;td align="center"&gt;&lt;bold&gt;WB4&lt;/bold&gt;&lt;/td&gt;&lt;td align="center"&gt;&lt;bold&gt;WB4C&lt;/bold&gt;&lt;/td&gt;&lt;td align="center"&gt;&lt;bold&gt;WB4T&lt;/bold&gt;&lt;/td&gt;&lt;td align="center"&gt;&lt;bold&gt;WB4C+V&lt;/bold&gt;&lt;/td&gt;&lt;td align="center"&gt;&lt;bold&gt;WB4T+V&lt;/bold&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align="left"&gt;&lt;bold&gt;Ciprofloxacin&lt;/bold&gt;&lt;/td&gt;&lt;td align="center"&gt;0.5&lt;/td&gt;&lt;td align="center"&gt;8&lt;/td&gt;&lt;td align="center"&gt;&amp;gt;32&lt;/td&gt;&lt;td align="center"&gt;1&lt;/td&gt;&lt;td align="center"&gt;1&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;&lt;bold&gt;Ciprofloxacin +&lt;/bold&gt;&lt;/td&gt;&lt;td align="center"&gt;0.5&lt;/td&gt;&lt;td align="center"&gt;8&lt;/td&gt;&lt;td align="center"&gt;&amp;gt;32&lt;/td&gt;&lt;td align="center"&gt;1&lt;/td&gt;&lt;td align="center"&gt;1&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;&lt;bold&gt;Vancomycin (1/4 MIC)&lt;/bold&gt;&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;&lt;bold&gt;Trovafloxacin&lt;/bold&gt;&lt;/td&gt;&lt;td align="center"&gt;0.12&lt;/td&gt;&lt;td align="center"&gt;0.25&lt;/td&gt;&lt;td align="center"&gt;4&lt;/td&gt;&lt;td align="center"&gt;0.25&lt;/td&gt;&lt;td align="center"&gt;0.12&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;&lt;bold&gt;Trovafloxacin +&lt;/bold&gt;&lt;/td&gt;&lt;td align="center"&gt;0.12&lt;/td&gt;&lt;td align="center"&gt;0.25&lt;/td&gt;&lt;td align="center"&gt;4&lt;/td&gt;&lt;td align="center"&gt;0.25&lt;/td&gt;&lt;td align="center"&gt;0.12&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;&lt;bold&gt;Vancomycin (1/4MIC)&lt;/bold&gt;&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="left"&gt;&lt;bold&gt;Vancomycin&lt;/bold&gt;&lt;/td&gt;&lt;td align="center"&gt;0.12&lt;/td&gt;&lt;td align="center"&gt;0.12&lt;/td&gt;&lt;td align="center"&gt;0.12&lt;/td&gt;&lt;td align="center"&gt;0.12&lt;/td&gt;&lt;td align="center"&gt;0.12&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>12289</offset><text>	MIC(mg/L)	 			 		WB4	WB4C	WB4T	WB4C+V	WB4T+V	 	Ciprofloxacin	0.5	8	&gt;32	1	1	 	Ciprofloxacin +	0.5	8	&gt;32	1	1	 	Vancomycin (1/4 MIC)						 	Trovafloxacin	0.12	0.25	4	0.25	0.12	 	Trovafloxacin +	0.12	0.25	4	0.25	0.12	 	Vancomycin (1/4MIC)						 	Vancomycin	0.12	0.12	0.12	0.12	0.12	 	</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>12571</offset><text>WB4: quinolone-susceptible but penicillin-resistant parent pneumococcus; WB4 C: ciprofloxacin-resistant derivative selected by passages on this drug; WB4 T: trovafloxacin-resistant derivative selected by passages on this drug; WB4 C+V or WB4 T+V: same as above cycled in presence of subinhibitory concentrations of vancomycin.</text></passage><passage><infon key="file">T2.xml</infon><infon key="id">T2</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>12898</offset><text>Mutations in topoisomerase IV (ParC and ParE) and gyrase (GyrA and GyrB) genes before and after cyclic exposure to ciprofloxacin, trovafloxacin, or either of these drugs plus vancomycin in a penicillin-resistant pneumococcal strain</text></passage><passage><infon key="file">T2.xml</infon><infon key="id">T2</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version="1.0" encoding="UTF-8"?&gt;
&lt;table frame="hsides" rules="groups"&gt;&lt;thead&gt;&lt;tr&gt;&lt;td align="center"&gt;&lt;bold&gt;Strain&lt;/bold&gt;&lt;/td&gt;&lt;td align="center"&gt;&lt;bold&gt;ParC&lt;/bold&gt;&lt;/td&gt;&lt;td align="center"&gt;&lt;bold&gt;ParE&lt;/bold&gt;&lt;/td&gt;&lt;td align="center"&gt;&lt;bold&gt;GyrA&lt;/bold&gt;&lt;/td&gt;&lt;td align="center"&gt;&lt;bold&gt;GyrB&lt;/bold&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align="center"&gt;&lt;bold&gt;WB4&lt;/bold&gt;&lt;/td&gt;&lt;td align="center"&gt;None&lt;/td&gt;&lt;td align="center"&gt;none&lt;/td&gt;&lt;td align="center"&gt;none&lt;/td&gt;&lt;td align="center"&gt;none&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="center"&gt;&lt;bold&gt;WB4C&lt;/bold&gt;&lt;/td&gt;&lt;td align="center"&gt;Ser79 &#8594; Tyr&lt;/td&gt;&lt;td align="center"&gt;none&lt;/td&gt;&lt;td align="center"&gt;none&lt;/td&gt;&lt;td align="center"&gt;Asp435 &#8594; Glu&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="center"&gt;&lt;bold&gt;WB4T&lt;/bold&gt;&lt;/td&gt;&lt;td align="center"&gt;Ser79 &#8594; Phe&lt;/td&gt;&lt;td align="center"&gt;none&lt;/td&gt;&lt;td align="center"&gt;Ser81 &#8594; Phe&lt;/td&gt;&lt;td align="center"&gt;none&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="center"&gt;&lt;bold&gt;WB4 C+V&lt;/bold&gt;&lt;/td&gt;&lt;td align="center"&gt;Ser79 &#8594; Tyr&lt;/td&gt;&lt;td align="center"&gt;none&lt;/td&gt;&lt;td align="center"&gt;none&lt;/td&gt;&lt;td align="center"&gt;none&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align="center"&gt;&lt;bold&gt;WB4 T+V&lt;/bold&gt;&lt;/td&gt;&lt;td align="center"&gt;None&lt;/td&gt;&lt;td align="center"&gt;none&lt;/td&gt;&lt;td align="center"&gt;none&lt;/td&gt;&lt;td align="center"&gt;none&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>13130</offset><text>Strain	ParC	ParE	GyrA	GyrB	 	WB4	None	none	none	none	 	WB4C	Ser79 &#8594; Tyr	none	none	Asp435 &#8594; Glu	 	WB4T	Ser79 &#8594; Phe	none	Ser81 &#8594; Phe	none	 	WB4 C+V	Ser79 &#8594; Tyr	none	none	none	 	WB4 T+V	None	none	none	none	 	</text></passage><passage><infon key="file">T2.xml</infon><infon key="id">T2</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>13346</offset><text>WB4: quinolone-susceptible but penicillin-resistant parent pneumococcus; WB4 C: ciprofloxacin-resistant derivative selected by passages on this drug; WB4 T: trovafloxacin-resistant derivative selected by passages on this drug; WB4 C+V or WB4 T+V: same as above cycled in presence of subinhibitory concentrations of vancomycin.</text></passage></document></collection>